More specifically, duloxetine was associated with a significant decrease in urinary excretion of MHPG.
Duloxetine was associated with a significant decrease in the major NE metabolites (NM, VMA, MHPG) and in whole body NE turnover.
Duloxetine 120 mg/day (n=6) was associated with a significant decrease in mean blood 5-HT (−0.53±0.21 nmol/ml; p=0.02).
The NE reuptake inhibitor was associated with a significant decrease in whole body NE turnover, as suggested by the decrease in the sum of (NE+NM+VMA+MHPG).
These gene expression changes were associated with a significant decrease in HPA axis reactivity in rats treated with escitalopram.
Ingestion of 200 mg of USE was associated with a significant decrease in susceptibility of RBC to hemolysis in rats.
This decrease was associated with a significant decrease in oxytocin and vasopressin immunoreactive levels, suggestive of an increased hormonal release.
Combination therapy also was associated with a significant decrease in proteinuria, at least in the short term.
It can therefore be concluded that there is no strong evidence that folic acid supplementation or fortification is associated with a significant decrease in the frequency of non-NTD congenital anomalies.
A decline in binding capacity occurred in both cell groups during culture and was associated with a significant decrease in progestin production.
Elimination of prospective crossmatching for sensitized patients was associated with a significant decrease in time on the waiting list (P < 0.01) and in waiting list mortality (P < 0.05).
